Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 90
2021 143
2022 93
2023 60
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

368 results

Results by year

Filters applied: . Clear all
Page 1
Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials.
Filippatos C, Ntanasis-Stathopoulos I, Sekeri K, Ntanasis-Stathopoulos A, Gavriatopoulou M, Psaltopoulou T, Dounias G, Sergentanis TN, Terpos E. Filippatos C, et al. Viruses. 2023 Mar 16;15(3):765. doi: 10.3390/v15030765. Viruses. 2023. PMID: 36992474 Free PMC article. Review.
This meta-analysis aims to assess the role of convalescent plasma treatment on the clinical outcomes of COVID-19 patients enrolled in randomized controlled trials (RCTs). ...However, COVID-19 outpatients treated with convalescen …
This meta-analysis aims to assess the role of convalescent plasma treatment on the clinical outcomes of COVID-19 …
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E, Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z. Li L, et al. JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044. JAMA. 2020. PMID: 32492084 Free PMC article. Clinical Trial.
IMPORTANCE: Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed. OBJECTIVE: To evaluate the efficacy and adverse effects of c …
IMPORTANCE: Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID- …
Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients.
Misset B, Piagnerelli M, Hoste E, Dardenne N, Grimaldi D, Michaux I, De Waele E, Dumoulin A, Jorens PG, van der Hauwaert E, Vallot F, Lamote S, Swinnen W, De Schryver N, Fraipont V, de Mey N, Dauby N, Layios N, Mesland JB, Meyfroidt G, Moutschen M, Compernolle V, Gothot A, Desmecht D, Taveira da Silva Pereira MI, Garigliany M, Najdovski T, Bertrand A, Donneau AF, Laterre PF. Misset B, et al. N Engl J Med. 2023 Oct 26;389(17):1590-1600. doi: 10.1056/NEJMoa2209502. Epub 2023 Oct 25. N Engl J Med. 2023. PMID: 37889107 Free PMC article. Clinical Trial.
BACKGROUND: Passive immunization with plasma collected from convalescent patients has been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are available regarding the use of convalescent plasma in patients with …
BACKGROUND: Passive immunization with plasma collected from convalescent patients has been regularly used to treat coronavirus …
COVID-19 convalescent plasma.
Tobian AAR, Cohn CS, Shaz BH. Tobian AAR, et al. Blood. 2022 Jul 21;140(3):196-207. doi: 10.1182/blood.2021012248. Blood. 2022. PMID: 34695186 Free PMC article.
As the coronavirus disease (COVID-19) pandemic led to a global health crisis, there were limited treatment options and no prophylactic therapies for those exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ...CCP should als …
As the coronavirus disease (COVID-19) pandemic led to a global health crisis, there were limited treatment options and no prop …
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, Savoy N, Giunta DH, Pérez LG, Sánchez MDL, Gamarnik AV, Ojeda DS, Santoro DM, Camino PJ, Antelo S, Rainero K, Vidiella GP, Miyazaki EA, Cornistein W, Trabadelo OA, Ross FM, Spotti M, Funtowicz G, Scordo WE, Losso MH, Ferniot I, Pardo PE, Rodriguez E, Rucci P, Pasquali J, Fuentes NA, Esperatti M, Speroni GA, Nannini EC, Matteaccio A, Michelangelo HG, Follmann D, Lane HC, Belloso WH; PlasmAr Study Group. Simonovich VA, et al. N Engl J Med. 2021 Feb 18;384(7):619-629. doi: 10.1056/NEJMoa2031304. Epub 2020 Nov 24. N Engl J Med. 2021. PMID: 33232588 Free PMC article. Clinical Trial.
The infused convalescent plasma had a median titer of 1:3200 of total SARS-CoV-2 antibodies (interquartile range, 1:800 to 1:3200). ...Total SARS-CoV-2 antibody titers tended to be higher in the convalescent plasma …
The infused convalescent plasma had a median titer of 1:3200 of total SARS-CoV-2 antibodies (interquartil …
Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial.
Ventura-Enríquez Y, Cabello-Gutiérrez C, Pérez-Calatayud ÁA, Cortina-De la Rosa E, Fareli-González CJ, Castillo-Juárez P, Carlos AP, Zavaleta-Martínez EO, Diaz-Padilla E, Murrieta S, Álvarez-Jiménez VD, Ponce-Medrano JAD, Casillas-Suárez C, Ocampo-Ocampo MA, Vargas-De-León C, Fernández-Sánchez V. Ventura-Enríquez Y, et al. Life (Basel). 2022 Nov 2;12(11):1767. doi: 10.3390/life12111767. Life (Basel). 2022. PMID: 36362922 Free PMC article.
Background: The use of convalescent plasma (CP) has been considered for its immunological mechanisms that could benefit patients in moderate and severe stages of COVID-19. ...Thirty-nine participants with moderate (II) and severe (III) stages of COV …
Background: The use of convalescent plasma (CP) has been considered for its immunological mechanisms that could benefit patien …
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14. Lancet. 2021. PMID: 34000257 Free PMC article. Clinical Trial.
BACKGROUND: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with …
BACKGROUND: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 a …
Convalescent plasma may not be an effective treatment for severe and critically ill covid-19 patients: A Systematic Review & Meta-Analysis of Randomized Controlled Trials.
Yang P, Wang J, Zheng R, Tan R, Li X, Liu X, Li Y, Yuan Z, Wang Y, Chen Q, Yu J. Yang P, et al. Heart Lung. 2022 May-Jun;53:51-60. doi: 10.1016/j.hrtlng.2022.01.019. Epub 2022 Feb 1. Heart Lung. 2022. PMID: 35149308 Free PMC article. Review.
BACKGROUND: Convalescent plasma treatment for severe and critically ill Corona Virus Disease 2019 (COVID-19) patients remains controversial. ...METHODS: A literature search was conducted in the electronic databases for the randomized controlled …
BACKGROUND: Convalescent plasma treatment for severe and critically ill Corona Virus Disease 2019 (COVID-19) pat …
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.
Park HS, Yin A, Barranta C, Lee JS, Caputo CA, Sachithanandham J, Li M, Yoon S, Sitaras I, Jedlicka A, Eby Y, Ram M, Fernandez RE, Baker OR, Shenoy AG, Mosnaim GS, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Lau B, Ehrhardt S, Baksh SN, Shapiro JR, Ou J, Na YB, Knoll MD, Ornelas-Gatdula E, Arroyo-Curras N, Gniadek TJ, Caturegli P, Wu J, Ndahiro N, Betenbaugh MJ, Ziman A, Hanley DF, Casadevall A, Shoham S, Bloch EM, Gebo KA, Tobian AAR, Laeyendecker O, Pekosz A, Klein SL, Sullivan DJ. Park HS, et al. medRxiv [Preprint]. 2023 Dec 15:2023.04.13.23288353. doi: 10.1101/2023.04.13.23288353. medRxiv. 2023. PMID: 37131659 Free PMC article. Updated. Preprint.
BACKGROUND: The COVID-19 convalescent plasma (CCP) viral specific antibody levels that translate into recipient post-transfusion antibody levels sufficient to prevent disease progression is not defined. METHODS: This secondary analysis correlated donor …
BACKGROUND: The COVID-19 convalescent plasma (CCP) viral specific antibody levels that translate into recipient …
368 results